Biotech Bull and Bear 3X ETFs | LABD LABU (2024)

LABD

NAV (Net Asset Value)$6.57As of Mar 07, 2024

1 Day NAV change$+0.26(+4.15%)As of Mar 07, 2024

LABU

NAV (Net Asset Value)$152.52As of Mar 07, 2024

1 Day NAV change$-6.58(-4.14%)As of Mar 07, 2024

LABDDirexion Daily S&P Biotech Bear 3X Shares

Daily Target

-300%

Intra-day Value

LABD.IV

Daily NAV

$6.57

Daily Market Price

$6.58

Expense Ratio
(gross/net %)

1.10 / 1.09*

Daily Volume

13,785,114

Security Identifier

25460G716

Inception Date

May 28, 2015

LABUDirexion Daily S&P Biotech Bull 3X Shares

Daily Target

+300%

Intra-day Value

LABU.IV

Daily NAV

$152.52

Daily Market Price

$152.45

Expense Ratio
(gross/net %)

1.01 / 1.01*

Daily Volume

1,985,609

Security Identifier

25460G120

Inception Date

May 28, 2015

Operational Updates

  • 01/23/2024
    Direxion's New ETF Alert Service. Get Price and Volume Alerts automatically via text message!
    Set Up Your ETF Alerts Today
  • 11/06/2023
    Direxion Announces Reverse Splits of TMF and LABU
    Read the Article

Documents & Downloads

These leveraged ETFs seek a return that is 300% or -300% of the return of their benchmark indexfor a single day.The funds should not be expected to provide three times or negative three times the return of the benchmark’s cumulative return for periods greater than a day.

Pricing & Performance

NAV and Market Price information as of 03/07/2024.

LABD

Direxion Daily S&P Biotech Bear 3X Shares

Net Asset Value (NAV)

$6.57Nav

$+0.26Change

+4.15%Change

Market Price Closing

$6.58Market

$+0.26Change

+4.11%Change

Premium / Discount

$+0.01Change from Last Day Trading

Premium/Discount tool

LABU

Direxion Daily S&P Biotech Bull 3X Shares

Net Asset Value (NAV)

$152.52Nav

$-6.58Change

-4.14%Change

Market Price Closing

$152.45Market

$-6.49Change

-4.08%Change

Premium / Discount

$-0.07Change from Last Day Trading

Premium/Discount tool

Loading chart...

1M3MYTD1Y3Y5Y10YSince
Inception
Expense Ratio*
(Gross / Net%)
Inception
Date
LABD NAV

1M

-33.33

3M

-60.18

YTD

-30.93

1Y

-58.34

3Y

-29.06

5Y

-55.49

10Y

Since
Inception

-55.13

Expense Ratio*
(Gross / Net%)

1.10 / 1.09*

Inception
Date

05/28/2015

LABD Market Close

1M

-33.30

3M

-60.21

YTD

-30.96

1Y

-58.52

3Y

-29.06

5Y

-55.51

10Y

Since
Inception

-55.14

Expense Ratio*
(Gross / Net%)

1.10 / 1.09*

Inception
Date

05/28/2015

LABU NAV

1M

36.05

3M

97.20

YTD

24.25

1Y

15.76

3Y

-58.98

5Y

-33.55

10Y

Since
Inception

-29.30

Expense Ratio*
(Gross / Net%)

1.01 / 1.01*

Inception
Date

05/28/2015

LABU Market Close

1M

35.81

3M

96.63

YTD

24.24

1Y

15.75

3Y

-59.01

5Y

-33.55

10Y

Since
Inception

-29.31

Expense Ratio*
(Gross / Net%)

1.01 / 1.01*

Inception
Date

05/28/2015

As of February 29, 2024

The Primary Listing Exchange is the NYSE Arca, Inc.

*The Net Expense Ratio includes management fees, other operating expenses and Acquired Fund Fees and Expenses. If Acquired Fund Fees and Expenses were excluded, the Net Expense Ratio would be 0.95%. The Funds’ adviser, Rafferty Asset Management, LLC (“Rafferty”), has entered into an Operating Expense Limitation Agreement with each Fund. Under the Operating Expense Limitation Agreement, Rafferty has contractually agreed to waive all or a portion of its management fee and/or reimburse the Funds for Other Expenses through September 1, 2024, to the extent that a Fund’s Total Annual Fund Operating Expenses exceed 0.95% of the Fund’s average daily net assets (excluding, as applicable, among other expenses, taxes, swap financing and related costs, acquired fund fees and expenses, dividends or interest on short positions, other interest expenses, brokerage commissions and extraordinary expenses). If these expenses were included, the expense ratio would be higher.

The performance data quoted represents past performance. Past performance does not guarantee future results. The investment return and principal value of an investment will fluctuate. An investor’s shares, when redeemed, may be worth more or less than their original cost. Current performance may be lower or higher than the performance quoted. Returns for performance under one year are cumulative, not annualized. For the most recent month-end performance please visit the funds’ website at direxion.com.

Short-term performance, in particular, is not a good indication of a fund’s future performance, and an investment should not be made based solely on returns. Because of ongoing market volatility, fund performance may be subject to substantial short-term changes. For additional information, see the fund’s prospectus.

Index Information

The S&P Biotechnology Select Industry Index (SPSIBITR) is provided by S&P Dow Jones Indices LLC and includes domestic companies from the biotechnology industry. The Index is a modified equal-weighted index that is designed to measure the performance of the biotechnology sub-industry based on the Global Industry Classification Standards (GICS). One cannot invest directly in an index.

Index Top Ten Holdings

% of Total
Cytokinetics

% of Total

2.81

%

Karuna Therapeutics Inc

% of Total

1.77

%

Acadia Pharmaceuticals

% of Total

1.71

%

Biohaven Ltd

% of Total

1.49

%

Amicus Therapeutics

% of Total

1.44

%

Blueprint Medc/D

% of Total

1.43

%

Arrowhead Pharmaceuticals Inc

% of Total

1.43

%

Bridgebio Pharma

% of Total

1.43

%

Moderna Inc

% of Total

1.42

%

Ultragenyx Pharma

% of Total

1.36

%

Index Sector Weightings

% of Total
Biotechnology

% of Total

99.99

%

Index data as of 12/31/2023. Index sector weightings and top holdings are subject to change.

View Daily Fund Holdings

Strategy and Benefits

You know that TRADING is different than investing. But the opportunity to take advantage of short-term trends is only won, if you get the direction right.

Whether you’re a bull or a bear, Direxion is with you. Our leveraged ETFs are powerful tools built to help you:

  • Magnify your short-term perspective with daily 3X leverage
  • Go where there’s opportunity, with bull and bear funds for both sides of the trade; and
  • Stay agile – with liquidity to trade through rapidly changing markets

Leveraged and inverse ETFs pursue daily leveraged investment objectives which means they are riskier than alternatives which do not use leverage. They seek daily goals and should not be expected to track the underlying index over periods longer than one day. They are not suitable for all investors and should be utilized only by investors who understand leverage risk and who actively manage their investments.

Distributions

LABD Direxion Daily S&P Biotech Bear 3X Shares

Record DateEx DatePay DateIncome DividendShort-Term Capital GainLong-Term Capital Gain
12/22/202312/21/202312/29/20230.08463
09/20/202309/19/202309/26/20230.19152
06/22/202306/21/202306/28/20230.09985
03/22/202303/21/202303/28/20230.21822
12/21/202212/20/202212/28/20220.09179

Record Date12/22/2023

Ex Date12/21/2023

Pay Date12/29/2023

Income Dividend0.08463

Short-Term Capital Gain

Long-Term Capital Gain

Record Date09/20/2023

Ex Date09/19/2023

Pay Date09/26/2023

Income Dividend0.19152

Short-Term Capital Gain

Long-Term Capital Gain

Record Date06/22/2023

Ex Date06/21/2023

Pay Date06/28/2023

Income Dividend0.09985

Short-Term Capital Gain

Long-Term Capital Gain

Record Date03/22/2023

Ex Date03/21/2023

Pay Date03/28/2023

Income Dividend0.21822

Short-Term Capital Gain

Long-Term Capital Gain

Record Date12/21/2022

Ex Date12/20/2022

Pay Date12/28/2022

Income Dividend0.09179

Short-Term Capital Gain

Long-Term Capital Gain

LABU Direxion Daily S&P Biotech Bull 3X Shares

Record DateEx DatePay DateIncome DividendShort-Term Capital GainLong-Term Capital Gain
12/22/202312/21/202312/29/20230.20968
09/20/202309/19/202309/26/20230.00202
06/22/202306/21/202306/28/20230.00868

Record Date12/22/2023

Ex Date12/21/2023

Pay Date12/29/2023

Income Dividend0.20968

Short-Term Capital Gain

Long-Term Capital Gain

Record Date09/20/2023

Ex Date09/19/2023

Pay Date09/26/2023

Income Dividend0.00202

Short-Term Capital Gain

Long-Term Capital Gain

Record Date06/22/2023

Ex Date06/21/2023

Pay Date06/28/2023

Income Dividend0.00868

Short-Term Capital Gain

Long-Term Capital Gain

Documents

Fund Documents

Tax Documents

Download the following Tax Reporting Documents

  • Form 8937
    (LABD 2020)

How to Buy

ETFs are generally available for purchase on exchanges, much like stocks—and can be bought and sold throughout the trading day whenever exchanges are open. Direxion ETFs cannot be purchased directly from Direxion, but are available for trading on most trading platforms.

We strongly recommend that you take the time to educate yourself on how leveraged and inverse ETFs function and behave in various market conditions before you endeavor to trade them in your account. It’s always a good idea to consult a financial advisor or brokerage account representative if you have questions about any ETFs.

Please note, your advisor or broker may charge commissions or other transaction fees.If you have any questions specific to Direxion products, please contact us direct at [emailprotected] or 866-476-7523.

Biotech Bull and Bear 3X ETFs | LABD LABU (2024)
Top Articles
Latest Posts
Article information

Author: Jeremiah Abshire

Last Updated:

Views: 6394

Rating: 4.3 / 5 (54 voted)

Reviews: 85% of readers found this page helpful

Author information

Name: Jeremiah Abshire

Birthday: 1993-09-14

Address: Apt. 425 92748 Jannie Centers, Port Nikitaville, VT 82110

Phone: +8096210939894

Job: Lead Healthcare Manager

Hobby: Watching movies, Watching movies, Knapping, LARPing, Coffee roasting, Lacemaking, Gaming

Introduction: My name is Jeremiah Abshire, I am a outstanding, kind, clever, hilarious, curious, hilarious, outstanding person who loves writing and wants to share my knowledge and understanding with you.